Advance Your Immunotherapy Drug Discovery

Translational Immuno-Oncology platform technologies to support your transition into the clinic.

CrownBio provides a range of integrated platform technologies for preclinical drug development over a variety of different cancer types. Our immuno-oncology portfolio employs integrated *in vitro*, *ex vivo*, and *in vivo* models along with innovative immunological analyses to inform preclinical decision making and help you confidently:

- Select qualified immunotherapy lead agents
- Assess PK/PD and cytotoxicity of immunotherapies
- Determine efficacy and response to treatment (including *in vitro* and *in vivo* models of resistance)
- Investigate combination therapies

**Animal Models**

- Syngeneic models (including bioluminescent models)
- Syngeneic NK models
- GEMM
- Murine allograft models (MuPrime™)
- Drug target humanized models (HuGEMM™/HuCELL™)
- Humanized mice
- MiXeno™ transient humanized models
- PDX-non-T-I/O models
- CAR-T therapy evaluation - PDX/CD19 targeting
- Oncolytic virus - PDX/cell line derived xenograft/syngeneic

**Immunological Assays**

- Phenotypic assays
- *In vitro* screening assays
- Tissue slides/arrays
- Immunohistochemistry
- FACS
- T cell based assays
- ADCC and CDC
- NK cell antibody-dependent cell-mediated cytotoxicity
- Complement-dependent cytotoxicity
- Luminex and MesoScale Discovery Development

**Contact Sales**
US: +1.855.827.6968
UK: +44 (0)870 166 6234
busdev@crownbio.com

**Schedule Scientific Consultation**
Request a consultation to discuss your project.
consultation@crownbio.com

**OncoExpress™**
Get Your Credentials Today
Visit: OncoExpress.crownbio.com

A JSR Life Sciences Company

Version 1.1

+1.855.827.6968 | busdev@crownbio.com | www.crownbio.com